Immunosuppression and immunomodulation in Sjogren's syndrome - What is the evidence? Does it relieve the sicca symptoms?

Mavragani, CP; Moutsopoulos, HM

dc.contributor.author	Mavragani, CP	en
dc.contributor.author	Moutsopoulos, HM	en
dc.date.accessioned	2014-03-01T01:54:36Z
dc.date.available	2014-03-01T01:54:36Z
dc.date.issued	2005	en
dc.identifier.issn	0341-051X	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/27443
dc.subject	Sjogren's Syndrome (SS)	en
dc.subject	autoimmune disease	en
dc.subject	immunosuppression	en
dc.subject	immunomodulation	en
dc.subject.classification	Rheumatology	en
dc.subject.other	DOUBLE-BLIND	en
dc.subject.other	CONTROLLED-TRIAL	en
dc.subject.other	DRY EYE	en
dc.subject.other	XEROSTOMIA	en
dc.subject.other	SALIVARY	en
dc.subject.other	CEVIMELINE	en
dc.subject.other	PLACEBO	en
dc.subject.other	ALPHA	en
dc.subject.other	INFLIXIMAB	en
dc.subject.other	MULTICENTER	en
dc.title	Immunosuppression and immunomodulation in Sjogren's syndrome - What is the evidence? Does it relieve the sicca symptoms?	en
heal.type	journalArticle	en
heal.language	German	en
heal.publicationDate	2005	en
heal.abstract	Sjogren's syndrome (SS), is a chronic autoimmune disorder, characterized by lymphocytic infiltration and destruction of the exocrine glands (mainly the salivary and the lacrimal glands) resulting in dry mouth and eyes. The symptoms of SS are chronic and sometimes devastating, compromising the quality of life at a major extent. Although SS is considered a classical autoimmune disorder, evidence for the use of immunosuppressive agents, the mainstay of therapy of diseases of autoimmune origin, is scarce. Cholinergic agents, such as pilocarpine and cevimeline are the cornerstone of current therapy of SS, while oral interferon and ciclosporine ocular drops seem to be of some benefit. In contrast, other immunosuppressive substances, such as methotrexate, azathioprine or anti-TNF agents, did not alleviate the sicca features associated with the disease. Corticosteroids, cyclophosphamide and nucleoside analogues are reserved for life threatening severe extraglandular manifestations of SS.	en
heal.publisher	GEORG THIEME VERLAG KG	en
heal.journalName	AKTUELLE RHEUMATOLOGIE	en
dc.identifier.isi	ISI:000227396800012	en
dc.identifier.volume	30	en
dc.identifier.issue	1	en
dc.identifier.spage	66	en
dc.identifier.epage	70	en